TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25982025
Drug: MenPF-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenPF-1 vaccine (25 μg or 50 μg doses)
Study: 23896353
Drug: Intravenous cortisol
Normalized name: Corticool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cortisol (100mg)
Study: 19526040
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days)
Study: 16904524
Drug: Clinical intervention
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical intervention including an information session, the use of a pain diary, and the possibility to contact a physician to adjust the pain medication
Study: 16904524
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment of pain by the staff radiation oncologist
Study: 15265053
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (0.1, 0.25, 0.5, 1, 2.5, 5, and 10 mg)
Study: 15265053
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (10 mg)
Study: 15265053
Drug: BIBN 4096
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBN 4096 BS (5 and 10 mg)
Study: 9119883
Drug: CM101 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM101 (7.5 micrograms/kg, 15 micrograms/kg, 24.75 micrograms/kg, 37.5 micrograms/kg) administered via i.v. infusion over 15 min, one cycle of therapy consisting of three treatments during 1 week.
Study: 2956983
Drug: Thymoxamine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine (0.15 mg kg‐1 loading dose followed by 0.15 mg kg‐1 h‐1)
Study: 2956983
Drug: Chlorpheniramine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (1.5 mg loading dose followed by 1.5 mg h‐1)
Study: 29500209
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded placebo)
Study: 29500209
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded cefuroxime axetil)
Study: 22694906
Drug: adjunctive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjunctive group interpersonal psychotherapy (IPT) for MDD
Study: 20353624
Drug: Rivastigmine 1.5
Normalized name: rivastigmine 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 1.5 mg once a day, increasing to 1.5 mg twice a day after seven days
Study: 9208532
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of TCM and chemotherapy (Group A)
Study: 9208532
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Group B)
Study: 1579962
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy (venesection/dextran 40)
Study: 24804185
Drug: Topical Achilles
Normalized name: Bos taurus achilles tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Achilles millefolium 5% gel (twice daily for four weeks) along with weekly intralesional Glucantime injections
Study: 24804185
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for four weeks) along with weekly intralesional Glucantime injections
Study: 24804185
Drug: Topical Achilles
Normalized name: Bos taurus achilles tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Achilles millefolium 5% gel
Study: 22161686
Drug: PTH(1-84) 100
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) 100 µg/day subcutaneously
Study: 10618940
Drug: Clonidine bolus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine bolus of 25 micrograms and infusion of 19 micrograms h‐1 added to 0.03% bupivacaine
Study: 10618940
Drug: Clonidine bolus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine bolus of 50 micrograms and infusion of 37 micrograms h‐1 added to 0.03% bupivacaine
Study: 1767060
Drug: 5 mg/mq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/mq of i.v. cisplatin administered 30-60 minutes before each radiation therapy session (Group A)
Study: 24965834
Drug: Human-powered nebuliser
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human-powered nebuliser with 2.5 mg dose of salbutamol
Study: 24965834
Drug: Electric nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electric nebuliser with 2.5 mg dose of salbutamol
Study: 22240597
Drug: voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.9 mg/day)
Study: 22240597
Drug: nateglinide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide (180 mg/day)
Study: 20061334
Drug: Lanreotide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (30 mg/2 weeks i.m. increasing to 30 mg/week i.m. at week 8 if mean GH >2.5 microg/l)
Study: 17028419
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (25 mg o.d. for 4 days)
Study: 28686474
Drug: Low-dose aripiprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aripiprazole (5 mg/day if <50 kg; 10 mg/day if ≥50 kg)
Study: 28686474
Drug: High-dose aripiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aripiprazole (10 mg/day if <50 kg; 20 mg/day if ≥50 kg)
Study: 25220550
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg + Dexamethasone 8 mg
Study: 23591120
Drug: Daily energy
Normalized name: CVS Daily Energy Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily energy restriction (DER)
Study: 19930566
Drug: 7.5% hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hypertonic saline in 6% dextran 70, single dose of 250 ml
Study: 15010401
Drug: Controlled-release codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release codeine (CC)
Study: 15010401
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine (A/C; 300 mg/30 mg)
Study: 30375070
Drug: Adenosine (Ado)
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine (Ado) 18-36 mg
Study: 30375070
Drug: Isoproterenol (Iso)
Normalized name: isoproterenol sulfate Metered Dose Inhaler [Medihaler-Iso]
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoproterenol (Iso) 3-20 µg/min
Study: 24421329
Drug: Pomalidomide +
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide + low-dose dexamethasone (POM+LoDEX)
Study: 22766815
Drug: Sun cream
Normalized name: CENTELLA ASIATICA TRITERPENOIDS 0.004 mg in 40 mg TOPICAL CREAM [EELHOE Sun Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sun cream with jellyfish sting inhibitor
Study: 22766815
Drug: Ordinary sun
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary sun cream
Study: 19541578
Drug: CNI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI at 25% of the initial dose + 1000 mg MMF b.i.d. (group 2; n = 13)
Study: 19541578
Drug: CNI-free MMF/prednisone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI-free MMF/prednisone-based treatment (group 1; n = 8)
Study: 12224369
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate tablets
Study: 31419490
Drug: Drug provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug provocation testing (DPT) to amoxicillin over 3 days
Study: 27660995
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC; n = 130)
Study: 25516195
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin (80 mg daily for 3 weeks)
Study: 25516195
Drug: Low-dose simvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose simvastatin (40 mg daily for 3 weeks)
Study: 23321148
Drug: Covered implants
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Covered implants (n=51)
Study: 23321148
Drug: Uncovered implants
Normalized name: Canker Cover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncovered implants (n=54)
Study: 18977549
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk prepared with Lactobacillus GG (LGG) and L. gasseri TMC0356
Study: 18977549
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk prepared with L. gasseri TMC0356
Study: 17501728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (delayed treatment, no treatment)
Study: 9658726
Drug: R-1 (CBDCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-1 (CBDCA 300 mg/m2/d on days 1-4, HIDAC 1 g/m2/bd on days 1-5, mitoxantrone/idarubicin 12/6 mg/m2/d on days 1-3)
Study: 9658726
Drug: R-2 (CBDCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-2 (CBDCA and G-CSF as above, HIDAC on alternate days, mitoxantrone/idarubicin 8/5 mg/m2/dose)
Study: 7980831
Drug: Response options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response options for frequency of alcohol use items in a self‐administered microcomputer interview
Study: 2588564
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific intralymphatic immunotherapy (autologous, cryopreserved, irradiated tumor cells)
Study: 2588564
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (300 mg per m2) administered 3 days before the autologous cell vaccine
Study: 2588564
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific intralymphatic immunotherapy
Study: 1138671
Drug: Intake of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake of 2,200 mg of phosphorus and 2,400 mg of calcium
Study: 31858835
Drug: Inhibition Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition Training (IT) group, received training based on a hybrid flanker Go/No-go task, 4 consecutive daily training sessions of 20 minutes each.
Study: 28041830
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase HCG support (single mid-luteal HCG injection)
Study: 24283136
Drug: Spray vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray vaccination with Poulvac E. coli (aroA-deficient mutant strain)
Study: 24283136
Drug: Simultaneous use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous use of vaccine with antibiotic ceftiofur sodium
Study: 24283136
Drug: Spray vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray vaccination
Study: 21150784
Drug: Idursulfase (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idursulfase (0.5 mg/kg weekly for 2 years)
Study: 18645347
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention and combination therapy with metformin and glimepiride
Study: 18645347
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral therapy (glimepiride + metformin + rosiglitazone)
Study: 18645347
Drug: Non-insulin-requiring group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin-requiring group
Study: 18645347
Drug: Insulin-requiring group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-requiring group
Study: 18645347
Drug: Non-insulin-requiring patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin-requiring patients
Study: 18645347
Drug: Insulin-requiring patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-requiring patients
Study: 17767120
Drug: Peppermint gel
Normalized name: Peppermint
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint gel
Study: 11548842
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (4 cycles of docetaxel 75 mg/m2 and doxorubicin 50 mg/m2)
Study: 9257210
Drug: Intrathecal opioid
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal opioid (10 micrograms/kg morphine and 25 micrograms fentanyl)
Study: 9257210
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intrathecal opioid, received 25 to 50 micrograms/kg fentanyl and 0.05 to 0.1 mg/kg midazolam intraoperatively)
Study: 24624878
Drug: Abnormal savda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal savda munziq (ASMq) at 0.1-1.0 mg/ml
Study: 20798196
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus Letrozole (L + Let)
Study: 12972100
Drug: Intravenous platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous platelet glycoprotein IIb/IIIa antagonists
Study: 11910657
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and oral medroxyprogesterone acetate 10 mg/day during the last 12 days of the month
Study: 11910657
Drug: Clodronate -
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate - oral clodronate 400 mg/day for 1 month out of every 3 months
Study: 11910657
Drug: Calcitonin -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin - nasal spray 100 IU/day
Study: 11910657
Drug: Clodronate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate plus Calcitonin - oral clodronate 400 mg/day for 1 month out of every 3 months plus calcitonin nasal spray 100 IU/day
Study: 8186713
Drug: Intermittent low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent low dosage schedule of Prednisolone at 0.75 mg kg‐1 day‐1 for 10 days at the beginning of each calendar month
Study: 28361171
Drug: nano-hydroxyapatite 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-hydroxyapatite 2% gel toothpaste fluoride free
Study: 28361171
Drug: fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoride gel toothpaste
Study: 21252486
Drug: Hypothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia therapy
Study: 11877686
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin therapy (WASA)
Study: 11877686
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy alone (ASA)
Study: 9561883
Drug: Preventive practices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive practices (diet and drugs)
Study: 7625118
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms rgp160 vaccine adjuvanted in alum and deoxycholate
Study: 3395106
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g every 6 h
Study: 3395106
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g every 8 h
Study: 20652275
Drug: Thiamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (150 mg, orally, once daily for 1 month)
Study: 17457441
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin daily (n=72)
Study: 15520068
Drug: Combination cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cisplatin, interferon, doxorubicin and fluorouracil (PIAF)
Study: 10866893
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia (GA) with propofol 1.5 mg/kg IV, remifentanil 0.125 microg/kg IV, maintained with desflurane (2%-4%) and nitrous oxide (60%).
Study: 9505980
Drug: Flunisolide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide 0.5 mg inhaled with and without oral charcoal
Study: 9505980
Drug: Flunisolide 1
Normalized name: flunisolide 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide 1 mg, 2 mg, and 3 mg inhaled with concomitant charcoal
Study: 9505980
Drug: Flunisolide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (all doses)
Study: 9505980
Drug: Flunisolide administered
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide administered at 10 PM
Study: 2860041
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 to 800 mg once daily for 12 weeks)
Study: 2860041
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 to 320 mg twice daily for 12 weeks)
Study: 30285519
Drug: SleepTrackTXT2 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SleepTrackTXT2 intervention (behavioral, non-pharmacological), additional text messages with recommendations for fatigue mitigation, weekly text messages promoting sleep.
Study: 16546481
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP; 3.6 g/kg)
Study: 16546481
Drug: Moderate-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein diet (MP; 1.8 g/kg)
Study: 16546481
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LP; 0.8 g/kg)
Study: 11086437
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: CDDP 50 mg on day 1, 5‐FU 500 mg/day from day 2 to day 7 and 5‐FU 500 mg/day for 2 weeks thereafter (FP treatment)
Study: 11086437
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: CDDP 50 mg at reservoir insertion and 5‐FU 1,000 mg for 5 hours thereafter (WHF treatment)
Study: 11086437
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 5‐FU 1,000 mg for 24 hours on day 1, day 3, and day 5 of every week with CDDP 5‐10 mg/day from day 1 to day 5 (intermittent F + low‐dose P treatment) for 3 weeks
Study: 9323551
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate injection (300 mg)
Study: 30359476
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (adjusted to achieve a serum level > 30 ng/mL) with calcium (1,200 mg)
Study: 30359476
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with calcium (1,200 mg)
Study: 11640942
Drug: Antiobsessive drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiobsessive drug treatment
Study: 2511700
Drug: Pentalong longo
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentalong longo (40 mg PETN)
Study: 2511700
Drug: Pentalong (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentalong (20 mg)
Study: 2511700
Drug: Pentalong longo
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentalong longo (40 mg PETN) with five layers of coating
Study: 29141164
Drug: Lomustine plus
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine plus Bevacizumab (combination group)
Study: 29141164
Drug: Lomustine alone
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine alone (monotherapy group)
Study: 23992877
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus erlotinib (p.o. 150 mg/day)
Study: 23992877
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus chemotherapy (gemcitabine/cisplatin or carboplatin/paclitaxel standard doses)
Study: 15104559
Drug: rhGH replacement
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH replacement therapy for 4 years
Study: 15104559
Drug: rhGH replacement
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH replacement therapy + alendronate (10 mg/day) for 3 years
Study: 15104559
Drug: alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alendronate treatment
Study: 9764990
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg/day for 6 months)
Study: 7836511
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg every 12 hours for five doses starting 4 days after LH surge)
Study: 2899719
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha 2‐interferon at doses of 2.5, 5, or 10 X 10(6) U/m2 intramuscularly thrice weekly for 12‐24 weeks